ArticleFrontiers in oncology2026
Thoracic SMARCA4-deficient undifferentiated tumor prone to misdiagnosis as lung adenocarcinoma: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thoracic SMARCA4-deficient undifferentiated tumor (T-SMARCA4-DUT) is a rare neoplastic entity with a high risk of being misdiagnosed. We report the case of a 64-year-old male initially suspected of having mediastinal lymphoma by contrast-enhanced chest computed tomography (CECCT), and pathologically diagnosed with metastatic poorly differentiated lung adenocarcinoma via cervical lymph node biopsy. Initial immunohistochemical (IHC) results showed TTF-1 (clone SPT24) (+), Napsin A (-), p40 (-), and next-generation sequencing (NGS) detected KRAS amplification and TP53 missense mutation. Combined chemotherapy plus immunotherapy initially shrank the tumor, but bilateral axillary lymphadenopathy subsequently developed. Pathological analysis of axillary metastases and supplementary IHC of the original cervical biopsy revealed SMARCA4/Brg1 (-), SOX2 (+) and TTF-1 (clone 8G7G3/1) (-), leading to a revised diagnosis of lymph node-metastatic T-SMARCA4-DUT. This case identifies the non-specific clinical features of T-SMARCA4-DUT and an inadequate initial IHC panel as the core causes for misdiagnosis and confirms that a definitive diagnosis requires testing for SMARCA4/Brg1, SOX2, and the highly specific TTF-1 (clone 8G7G3/1).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.